R&D Innovation
The company’s R&D team was founded in 2002 and has grown to a core team consisting of nearly 200 professional researchers, including numerous senior scientists with over 10 years of experience in pharmaceutical R&D.
The R&D center is equipped with many internationally advanced production equipment and technologies that constitute a complete system for new drug R&D projects. After years of efforts, this system has transformed into an all-round scientific research system encompassing information research and survey, product project establishment, chemical synthesis, quality research, formulation research, and pilot scale production.
-
R&D team was Established in
2002 -
Professional researchers
200 -
Drug development experience of core members
10years
Currently, the company has established three R&D technological platforms, namely the “new injection process platform” “large compound formulation platform” “new lyophilization platform” Furthermore, its R&D platforms are extending to cover oral solid formation and new drug delivery system.
New injection process platform
Large compound formulation platform
New lyophilization platform
The R&D center is equipped with hundreds of pharmaceutical R&D instruments, such as high performance liquid chromatography system, ultra high performance liquid chromatography, gas chromatograph, inductively coupled plasma emission spectrometer, inductively coupled plasma emission mass spectrometer, high performance liquid chromatography-mass spectrometry system, amino acid analyzer, ion chromatography system, ultraviolet spectrophotometer, drug stability testing chamber, freeze dryer, insoluble particle detector, one millionth of a balance, PH meter, muffle furnace, and various other experimental equipment necessary for synthesis.
Leveraging its own technological advantages and guided by clinical and market demands, Weixinkang is focused on the R&D of drug products with high market demand, high technological requirement and low competition. The company adheres to a step-wise R&D strategy of “one pipeline for marketing, one for backup, one under research, and one for project establishment.” After years of unremitting innovation, the company has gained obvious competitive edges in various fields of expertise and developed and cultivated a series of superior products with clear clinical efficacy and promising market prospects that filled market gaps in China.
